Solid Biosciences (SLDB) EBIT (2017 - 2024)
Historic EBIT for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to -$39.9 million.
- Solid Biosciences' EBIT fell 7918.71% to -$39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$129.7 million, marking a year-over-year decrease of 2443.69%. This contributed to the annual value of -$129.7 million for FY2024, which is 2443.69% down from last year.
- Per Solid Biosciences' latest filing, its EBIT stood at -$39.9 million for Q4 2024, which was down 7918.71% from -$35.2 million recorded in Q3 2024.
- Solid Biosciences' EBIT's 5-year high stood at -$19.0 million during Q2 2020, with a 5-year trough of -$39.9 million in Q4 2024.
- For the 4-year period, Solid Biosciences' EBIT averaged around -$26.9 million, with its median value being -$26.8 million (2023).
- As far as peak fluctuations go, Solid Biosciences' EBIT soared by 3558.7% in 2023, and later tumbled by 7918.71% in 2024.
- Quarter analysis of 4 years shows Solid Biosciences' EBIT stood at -$21.3 million in 2020, then tumbled by 61.92% to -$34.6 million in 2022, then skyrocketed by 35.59% to -$22.3 million in 2023, then plummeted by 79.19% to -$39.9 million in 2024.
- Its EBIT stands at -$39.9 million for Q4 2024, versus -$35.2 million for Q3 2024 and -$27.8 million for Q2 2024.